PHIO PHARMACEUTICALS CORP (PHIO) Stock News
NASDAQ:PHIO - Nasdaq - US71880W5013 - Common Stock - Currency: USD
PHIO Latest News, Press Releases and Analysis
These stocks have an unusual volume in today's session
In today's session, these stocks are experiencing unusual volume.
Top movers in Thursday's session
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
We Asked Retail What's Next For Phio Pharma After Monday's Blistering Rally: Most See More Room To Run
Around 34% foresee a pullback, while 13% are uncertain due to the stock's volatility.
What's Going On With Phio Pharmaceuticals Stock Today?
Phio Pharmaceuticals stock drops 39.1% after announcing a $3.19 million direct offering and concurrent private placement.
Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why
On Monday, Phio Pharmaceuticals Corp. (NASDAQ:PHIO) stock skyrocketed with a strong session volume of 201.04 million, compared to the average volume of 362.72k, according to data from Benzinga Pro. Phio reported pathologic responses for patients enrolled in the 2nd cohort, which includes two patients with a complete response or 100% tumor clearance. Phio’s ongoing Phase 1b clinical study is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in Stages 1, 2
Phio Pharma Stock Quadruples On Positive Data From Cancer Treatment Trial: Retail’s Elated
CEO Robert Bitterman highlighted the potential of Phio’s proprietary INTASYL RNAi technology, which targets proteins that hinder the body’s immune response to cancer.
